Abstract
In this paper we analyze differences in the timing of approval of important pharmaceuticals in France and the United States between the years 1970 and 1988. Our hypothesis is that the timing of approvals will be similar in both countries because of their similar approval processes and objectives. We analyze differences in the delays over time, by the a priori assessment by the FDA concerning a drug’s innovativeness, and by drug therapeutic category. We test the hypotheses, for example, that US approvals would be relatively fast for drugs which the FDA had initially designated as particularly innovative, and for drugs treating cardiovascular illnesses, the disease group with the highest age-adjusted mortality rate. The observation that one country consistently lagged behind the other in approving new drugs might indicate that the lagging country is either more rigorous, or perhaps less efficient, than the other.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Organization for Economic Cooperation and Development, Health Care Systems in Transition: The Search for Efficiency, Paris: OECD, 1990.
Peltzman S, “An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments,” Journal of Political Economy 8:1049–1091, 1973.
Wiggins SN, “Product Availability Regulation and New Drug Introductions: Some New Evidence from the 1970s,” Review of Economics and Statistics 63:615–619, 1981.
Thomas LG, “Regulation and Firm Size: FDA Impacts on Innovation,” RAND Journal of Economics 21:4(497–517), Winter 1990.
Grabowski HG, Vernon JM, and Thomas LG, “Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry,” Journal of Law and Economics 2:133–163, 1978.
Grabowski HG, “Regulation and the International Diffusion of Pharmaceuticals,” in Helms RB (ed), The International Supply of Medicines: Implications of U.S. Regulatory Reform, (pp. 5–36), Washington, DC, American Enterprise Institute for Public Policy Research, Washington DC, 1980.
Burstall ML, “Europe after 1992: Implications for Pharmaceuticals,” Health Affairs, 157–171, Fall 1991.
Fielding JE and Lancry PJ, “Lessons from France — ‘Vive la Difference’: The French Health Care System and US Health System Reform,” Journal of the American Medical Association 270(6): 748–756, August 11, 1993.
Rodwin VG and Sandier S, “Health Care under French National Health Insurance,” Health Affairs 12(3):111–131, Fall 1993.
Andersson F, “The Drug Lag Issue: The Debate Seen From An International Perspective,” International Journal of Health Services, 22:53–72, 1992.
Wardell WM, “Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison, Clinic. Pharmacol. Ther. 4: 773–790, 1973.
Wardell WM, “The Drug Lag Revisited: Comparison by Therapeutic Area of Patterns of Drugs Marketed in the United States and Great Britain from 1972 through 1976,” Clin. Pharmacol. Ther. 24:499–524, 1978.
Grabowski HG and Vernon JM, “Innovation and Invention — Consumer Protection Regulation in Ethical Drugs,” American Economic Review 67:359–364, 1977.
Berlin H and Jonsson B, “International Dissemination of New Drugs: A Comparative Study of Six Countries,” Managerial and Decision Economics 7:235–242, 1986.
Kaitin K, “Reply to ‘Understanding Comparisons of Drug Introductions between the United States and the United Kingdom’” Clinical Pharmacological Therapeutics 46:146–148, 1989.
Kaitin K et al., “The Drug Lag: An Update of New Drug Introductions in the United States and in the United Kingdom, 1977 through 1987,” Clinical Pharmacological Therapeutics 46:121–138, 1989.
Simmons HE, “The Drug Regulatory System of the United States Food and Drug Administration: A Defense of Current Requirements for Safety and Efficacy, International Journal of Health Services 4:95–107, 1974.
Coppinger PL, Peck CC, and Temple RJ, “Understanding Coimparisons of Drug Introductions between the United States and the United Kingdom,” Clin. Pharm. Ther. 46:139–145, 1989.
Parker JES, “Who Has A Lag?” Managerial and Decision Economics 10:299–309, 1989.
Parker JES, “Who Has A Lag?” J. Soc. Admin. Pharm., 6:138–152, 1989.
DeHaen P, “The Drug Lag — Does It Exist in Europe?” Drug Intell. Clin. Pharm. 9:144–150, 1975.
Parker JES, The International Diffusion of Pharmaceuticals, Macmillan, London, 1984.
Hass AE Jr, “Where Drug Marketing Patterns Are Similar,” Medical Marketing and Media 18:78–83, 1983.
Schweitzer S, Salehi H, and Boling N, “The Social Drug Lag,” Social Science and Medicine 21:10(1077–1082), 1985.
Grabowski HG, “Medicaid Patients’ Access to New Drugs,” Health Affairs 7:5(102–114), 1988.
Grabowski HG, Schweitzer SO, and Shiota R, “The Effect of Medicaid Formularies on the Availability of New Drugs,” PharmacoEconomics 1 (supp):(32–40), 1992.
Drug Facts and Comparisons, 1992 edition (St. Louis: Facts and Comparisons), 1992.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Schweitzer, S.O. (1996). An International Comparison of the Approval of New Pharmaceuticals. In: Geisler, E., Heller, O. (eds) Managing Technology in Healthcare. Management of Medical Technology, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1415-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1415-8_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8614-1
Online ISBN: 978-1-4613-1415-8
eBook Packages: Springer Book Archive